Oramed Announces $50 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules
NEW YORK, Nov. 3, 2021 /PRNewswire/ — Oramed Pharmaceuticals Inc. (“Oramed” or the “Company”) (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, today announced that it has entered into definitive agreements with several institutional and accredited investors for the sale and issuance, in a registered direct […]
